Zydus Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Zydus Therapeutics sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Zydus Therapeutics: 15 sponsored US clinical trials, 3 recruiting.
Zydus Therapeutics sponsors 15 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 9 completed. 1 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Nonalcoholic Steatohepatitis, with 2 trials.
Top-decile sponsor footprint
Zydus Therapeutics ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
15 total, page 1 of 1
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
NCT06825559
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
NCT06427395
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
NCT05045482
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
NCT07023835
Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US
NCT05211284
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
NCT05133336
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
NCT05011305
A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function
NCT04446507
Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function
NCT04469920
Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male Subjects
NCT04112446
Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
NCT03863574
Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)
NCT03639623
Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)
NCT03617263
Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis
NCT03112681
Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
NCT03061721
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 9 |
| Phase 3 | 1 |
What is open in the Zydus Therapeutics pipeline
3 recruiting of 15 indexed (20% open); 9 completed (60%).
Phase mix: 1 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Nonalcoholic Steatohepatitis (2 trials), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Zydus Therapeutics: open-pipeline peers nationwide
Peers matched on 15 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Zydus Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
Related
What to do with this Zydus Therapeutics page
15 registered trials is a research-attention snapshot, not an endorsement of Zydus Therapeutics or any single study.
- 3 of Zydus Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Nonalcoholic Steatohepatitis is the condition Zydus Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Nonalcoholic Steatohepatitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Zydus Therapeutics pipeline card: 15 registered trials from official public datasets.Report a data error.